Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
43
HIMS Quote, Financials, Valuation and Earnings
Last price:
$35.58
Seasonality move
:
22.43%
Day range:
$34.32 - $35.95
52-week range:
$23.97 - $72.98
Dividend yield:
0%
P/E ratio:
65.56x
P/S ratio:
3.98x
P/B ratio:
13.89x
Volume:
11.8M
Avg. volume:
13.1M
1-year change:
31.82%
Market cap:
$8.1B
Revenue:
$1.5B
EPS (TTM):
$0.54
Analysts' Opinion
-
Consensus RatingHims & Hers Health, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 8 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $44.36, Hims & Hers Health, Inc. has an estimated upside of 25.11% from its current price of $35.46.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $25.00 representing 100% downside risk from its current price of $35.46.
Fair Value
-
According to the consensus of 11 analysts, Hims & Hers Health, Inc. has 25.11% upside to fair value with a price target of $44.36 per share.
HIMS vs. S&P 500
-
Over the past 5 trading days, Hims & Hers Health, Inc. has overperformed the S&P 500 by 2.5% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Hims & Hers Health, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Hims & Hers Health, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Hims & Hers Health, Inc. reported revenues of $599M.
Earnings Growth
-
Hims & Hers Health, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Hims & Hers Health, Inc. reported earnings per share of $0.06.
Enterprise value:
8.6B
EV / Invested capital:
--
Price / LTM sales:
3.98x
EV / EBIT:
64.95x
EV / Revenue:
3.87x
PEG ratio (5yr expected):
2.61x
EV / Free cash flow:
73.74x
Price / Operating cash flow:
75.81x
Enterprise value / EBITDA:
49.12x
Gross Profit (TTM):
$1.4B
Return On Assets:
10.57%
Net Income Margin (TTM):
6.05%
Return On Equity:
25.63%
Return On Invested Capital:
13.77%
Operating Margin:
3.04%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $792.6M | $1.2B | $2.2B | $401.6M | $599M | |
| Gross Profit | $634.4M | $877.3M | $1.4B | $270.4M | $365.2M | |
| Operating Income | -$42M | $36.5M | $131.8M | $23.2M | $18.2M | |
| EBITDA | -$33.1M | $50.2M | $174.3M | $27.6M | $35.8M | |
| Diluted EPS | -$0.17 | $0.43 | $0.54 | $0.32 | $0.06 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $274.2M | $233.5M | $250.2M | $326.4M | $845.3M | |
| Total Assets | $420.1M | $382.8M | $413.9M | $602.3M | $2.2B | |
| Current Liabilities | $52.5M | $66.8M | $82.5M | $152.6M | $450.8M | |
| Total Liabilities | $64.9M | $71.9M | $85.3M | $162.2M | $1.7B | |
| Total Equity | $355.2M | $310.9M | $328.6M | $440.1M | $581M | |
| Total Debt | -- | $4.1M | $2.8M | $9.6M | $1.1B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $44.8M | $186.7M | $321.7M | $85.3M | $148.4M | |
| Cash From Investing | -$26.8M | $18.9M | -$958.5M | -$10.4M | -$887.4M | |
| Cash From Financing | -$18M | -$98.2M | $816.9M | -$38.8M | -$38.7M | |
| Free Cash Flow | $26.9M | $149.6M | $116.1M | $79.4M | $79M | |
HIMS
Sector
Market Cap
$8.1B
$28.5M
Price % of 52-Week High
48.59%
51.36%
Dividend Yield
0%
0%
Shareholder Yield
-1.79%
-1.55%
1-Year Price Total Return
31.82%
-20%
Beta (5-Year)
2.372
0.497
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$34.20
200-day SMA
Sell
Level
$45.80
Bollinger Bands (100)
Sell
Level
36.9 - 52.92
Chaikin Money Flow
Sell
Level
-185.9M
20-day SMA
Sell
Level
$35.90
Relative Strength Index (RSI14)
Sell
Level
46.90
ADX Line
Sell
Level
14.73
Williams %R
Neutral
Level
-38.6691
50-day SMA
Sell
Level
$38.66
MACD (12, 26)
Sell
Level
-1.45
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Neutral
Level
466.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (15.082)
Buy
CA Score
(Annual)
Level (1.9929)
Buy
Beneish M-Score
(Annual)
Level (-3.0606)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-2.245)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
Stock Forecast FAQ
In the current month, HIMS has received 2 Buy ratings 8 Hold ratings, and 1 Sell ratings. The HIMS average analyst price target in the past 3 months is $44.36.
-
Where Will Hims & Hers Health, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Hims & Hers Health, Inc. share price will rise to $44.36 per share over the next 12 months.
-
What Do Analysts Say About Hims & Hers Health, Inc.?
Analysts are divided on their view about Hims & Hers Health, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Hims & Hers Health, Inc. is a Sell and believe this share price will drop from its current level to $25.00.
-
What Is Hims & Hers Health, Inc.'s Price Target?
The price target for Hims & Hers Health, Inc. over the next 1-year time period is forecast to be $44.36 according to 11 Wall Street analysts, 2 of them rate the stock a Buy, 1 rates the stock a Sell, and 8 analysts rate the stock a Hold.
-
Is HIMS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Hims & Hers Health, Inc. is a Hold. 8 of 11 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of HIMS?
You can purchase shares of Hims & Hers Health, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Hims & Hers Health, Inc. shares.
-
What Is The Hims & Hers Health, Inc. Share Price Today?
Hims & Hers Health, Inc. was last trading at $35.58 per share. This represents the most recent stock quote for Hims & Hers Health, Inc.. Yesterday, Hims & Hers Health, Inc. closed at $35.46 per share.
-
How To Buy Hims & Hers Health, Inc. Stock Online?
In order to purchase Hims & Hers Health, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get HIMS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
HIMS
Sector
P/E ratio
65.56x
24.20x
PEG ratio
2.61x
-0.01x
P/B ratio
13.89x
1.84x
Price / LTM sales
3.98x
1.60x
Growth Metrics
HIMS
Sector
Revenue growth
49.16%
4.62%
Earnings growth
-80.29%
10.88%
Revenue (5-year growth)
78.03%
6.45%
Earnings forecast
$0.19
-$0.18
Profitability
HIMS
Sector
Profitability FY 2024
$1.2B
$3.6M
Return on invested capital
13.77%
-32.02%
Return on assets
10.57%
-28.31%
Return on equity
25.63%
-38%
Earnings Date
Last Earnings Date
Nov
3
Next Earnings Date
Feb
23
Estimated Next Earnings Date
Feb
2
Balance Sheet
HIMS
Sector
Total cash
$629.7M
$26.1M
Short term investments
$79.7M
$25.7M
Total assets
$724.8M
$76.6M
Long term debt
$1.1B
$3.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
69
RGC alert for Jan 7
Regencell Bioscience Holdings Ltd. [RGC] is up 58.95% over the past day.
Buy
69
WDC alert for Jan 7
Western Digital Corp. [WDC] is down 8.88% over the past day.
Buy
75
DRUG alert for Jan 7
Bright Minds Biosciences, Inc. [DRUG] is up 2.99% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
